ClinicalTrials.gg
RecruitingNCT06109142VITALUpdated Sep 19, 2024

Clearance of Vasoactive Metabolites With Blood Purification

An observational study in Critically Ill Patients, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris — 15 open to participants now, 16 under way, 3 of them phase 3. Shock, Septic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
11th of 13
30 · median 110
Started
2024
with 2 others
Observational
13 of 30
7 open now
Primary completion
2026-03
later than 5 of 15 live
Registered
22nd of 30
by date

Among the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, this one is the 11th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 22nd registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

15 of the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Extracorporeal blood purification is a supportive therapy in the management of patients with sepsis or vasoplegic shock. The pathophysiology of sepsis is based on an inappropriate host response to infection. Certain medical devices with higher adsorption capacity make it possible to limit this inappropriate response and could thus improve the hemodynamics of patients in septic or vasoplegic shock. The preliminary experience of the investigators from clinical data of vasopressor withdrawal in pediatric patients treated with oXiris shows a 50% reduction in the vasopressor score, Vaso Inotropic Score (VIS), for 40% of patients within 24 hours following the start of treatment. Similar results were found in adult patients treated for severe COVID-19 or vasoplegic shock by the other centers participating in the study.

Cytokine purification is an important physiological effect of purification membranes. However, this may not fully explain the rapid hemodynamic improvement of patients treated with an oXiris membrane.

The role of angiotensin metabolites (Ang 1-5, 1-7, 1-9) in the systemic vascular tone of patients has been recently discussed. The administration of angiotensin 2 in vasoplegic shock in adults helps correct hypotension. In the group of patients with increased renin, this treatment was associated with a reduction in mortality. Indeed, increased renin associated with dysfunction of Angiotensin Converting Enzyme (ACE) leads to an accumulation of Angiotensin 1 which degrades to Ang 1-7.

The hypothesis f the investigators is that the concentration of Ang 1 and Ang 1-7 is elevated in cases of vasoplegic shock and that the clearance of these vasodilator peptides by blood purification is associated with clinical improvement.

Read the detailed description

This is a pilot study, non-interventional research involving the human subjects, category 3, aimed at measuring the clinical and biological the clinical and biological effects of using the oXiris hemofiltration hemofiltration membrane.

As part of the treatment: oXiris membrane hemofiltration with Prismaflex system, Phoxylium or Hémosol B0 dialysis solution, upper or lower dialysis catheter. Anticoagulation with heparin, citrate or none in case of severe haemostasis disorders. Treatment volume of 35 ml/kg/h maximum.

For research purposes: collection of additional blood tubes (2 x 5mL heparinized tube) added to the usual samples, at the following times:

Baseline (before starting treatment), under hemofiltration at 24h +/- 6h of treatment and at 72 hours +/- 12 hours.

These samples will be analyzed by liquid chromatography - mass spectrometry / mass spectrometry (LC-MS/MS) by Attoquant diagnostics®, a laboratory specialized in analyses of the Renin-Angiotensin system. The angiotensins assayed are Angiotensin I, II, III and IV, as well as the intermediate peptides (1-5, 1-7, 1-9, 2-10, 2-7 and 3-7) and regulatory enzymes (renin, angiotensin converting enzyme, angiotensin 2-converting enzyme and neprilysin).

Angiotensin metabolites have a very short half-life. Their depends on enzyme activity and degradation by circulating proteases. Two techniques are used to determine circulating concentration rapid treatment with protease inhibitors or the equilibrium technique.

For the equilibrium technique, samples are incubated again to restore metabolite concentration prior to analysis. The samples at 3 time points (Baseline, H24 and H72) are analyzed using the equilibrium. The H24 sample will also be analyzed with a protease inhibitor pre-treatment.

Patients will be monitored for 3 months (90-day mortality) using data collected collected in the course of care.

Data from medical records and biological analyses will be entered into an eCRF. Data management will be carried out throughout the study, to enable baseline freezing and statistical analysis as early as possible after the end of the last patient's follow-up.

03

Conditions studied

  • Critically Ill Patients

Browse trials for

Keywords

  • Intensive care
  • Septic shock
  • Inflammatory mediators
  • Renin Angiotensin System
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The target population for pediatric resuscitation concerns:

  • Patients in septic shock requiring extra-renal purification, i.e. 10-20 patients/year
  • Perioperative liver transplant patients, 20% of whom require extra-renal purification for multi-visceral failure associated with shock vasoplegic (5-10 patients/year)

For adult resuscitations:

  • Patients in septic shock requiring extra-renal purification, i.e. 10-20% of these patients (30 patients per center per year for 2 centers)
  • Perioperative patients of major abdominal surgery with multi-organ renal failure requiring extra-renal purification (20 patients per year for a center).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to intensive care with vasoplegic shock (hemodynamic support by noradrenaline).
  • Adult or child ≥ 6 years and 30kg
  • Indication for extrarenal purification for acute, chronic renal failure, oliguric hydrosodic overload, metabolic acidosis or severe hydroelectrolyte disorder
  • Clinician's decision to use an oXiris hemofilter with blood purification capability
  • For adult patients: no opposition from the patient (or person of trust or close friend if the patient is unable to be informed)
  • For minor patients: no opposition of the holders of parental authority

Exclusion criteria

Exclusion Criteria:

  • No need for hemofiltration.
  • Citrate anticoagulation of the hemofiltration circuit
  • Inclusion in a category 1 or 2 interventional study protocol. Patients included in category 3 interventional research will be able to participate in the study after assessment by the physician.
  • Patient under judicial protection and adults under guardianship or curatorship.
  • Patient with no social security affiliation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. 50% reduction in vasoinotropic score within 24 hours of initiation on oXiris.

    Vaso-inotropic score calculated at baseline and H24. (Minimum 0 = better outcome)

    Time frame: Baseline - 24 hours

Secondary outcomes

  1. Evolution of the vaso-inotropic score within 72 hours of management

    Vaso-inotropic score calculated at baseline - 3 hours - 6 hours - 12 hours - 24 hours - 48 hours - 72 hours (Minimum 0 = better outcome)

    Time frame: Baseline - 3 hours - 6 hours - 12 hours - 24 hours - 48 hours - 72 hours

  2. Quantitative determination of angiotensins (Ang I, II, III, IV, 1-5, 1-7, 1-9, 2-7, 2-10 and 3-7) and regulatory enzymes (renin, angiotensin-converting enzyme, angiotensin-converting enzyme 2 and neprilysin).

    Dosage of angiotensins (Ang I, II, III, IV, 1-5, 1-7, 1-9, 2-7, 2-10 and 3-7) and regulatory enzymes (renin, angiotensin-converting enzyme, angiotensin-converting enzyme 2 and neprilysin) by LC/MS

    Time frame: Baseline - 24 hours - 72 hours

  3. Clearance of endothelial permeability markers (soluble E-selectin, thromboxane A2, endothelium-derived relaxing factor, bradykinin).

    Dosage of Clearance of endothelial permeability markers (soluble E-selectin, thromboxane A2, endothelium-derived relaxing factor, bradykinin) by RT-PCR

    Time frame: Baseline - 24 hours - 72 hours

  4. Markers of sepsis-induced immunosuppression expressed by HLA-DR monocytes in flow cytometry and selected cytokines (IL-1 beta, IL-6, IL-8, IL-10, TNF-alpha).

    Identification of Markers of sepsis-induced immunosuppression expressed by HLA-DR monocytes in flow cytometry and selected cytokines (IL-1 beta, IL-6, IL-8, IL-10, TNF-alpha) by flow cytometry

    Time frame: Baseline - 24 hours - 72 hours

  5. Mortality at 90 days

    the correlation between concentrations of metabolites of angiotensin and 90-day mortality

    Time frame: Baseline - 24 hours - 90 days

  6. haemodynamic response (concentrations of metabolites of angiotensin) at 24 hours of treatment with oXiris.

    the concentrations of metabolites of angiotensin

    Time frame: Baseline - 24 hours - 90 days

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2026, 20 months after the start.

Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 20 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 31, 2023
StartActual
Jul 11, 2024
Primary completionEst.
Mar 11, 2026
CompletionEst.
Jun 11, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06109142
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Jul 11, 2024
Primary completion
Mar 11, 2026 (estimated)
Completion
Jun 11, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Pierre Tissieres
Contact
pierre.tissieres@aphp.fr
0145213205
Pierre Tissieres
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion